MERKEL CELL CARCINOMA
Clinical trials for MERKEL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MERKEL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for MERKEL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cocktail aims to turn tumors against themselves
Disease control OngoingThis early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cell therapy shows promise for tough cancers
Disease control OngoingThis phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Transplant patients with skin cancer get new hope from engineered virus
Disease control OngoingThis study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy drug aims to stop rare skin cancer's return
Disease control OngoingThis study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to shrink skin cancer before surgery
Disease control OngoingThis phase 2 trial is testing whether giving a combination of two drugs—lenvatinib and pembrolizumab—before surgery can help people with Merkel cell carcinoma. The study involves 26 participants with stage II, III, or IV disease. The main goal is to see if the treatment leads to …
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy targets hard-to-treat skin cancer
Disease control OngoingThis study tests a combination of targeted radiation (CART) and the immunotherapy drug avelumab in 18 people with advanced Merkel cell carcinoma that has spread or cannot be removed by surgery. The goal is to see if this approach can slow or stop the cancer from growing. Particip…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to shrink advanced skin cancer tumors
Disease control OngoingThis study tests whether adding focused radiation to a two-drug immunotherapy combination works better than the drugs alone for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. About 50 adults with cancer that has spread or cannot be removed will rec…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Walk or cycle before cancer treatment: new study tests exercise boost
Disease control OngoingThis early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …
Matched conditions: MERKEL CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy before surgery shows promise for rare skin cancer
Disease control OngoingThis study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Triple immunotherapy attack shows promise for tough skin cancer
Disease control OngoingThis study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental cocktail aims to revive immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Matched conditions: MERKEL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:34 UTC
-
New scan could spot hidden tumors more accurately
Diagnosis OngoingThis study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…
Matched conditions: MERKEL CELL CARCINOMA
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Blood markers could spot hidden skin cancer return
Knowledge-focused OngoingThis study follows 35 people with Merkel cell carcinoma, a rare and aggressive skin cancer, to see if two blood markers (T-antigen antibodies and miR-375) can detect when the cancer comes back. Currently, follow-up relies on physical exams and scans, which may miss early recurren…
Matched conditions: MERKEL CELL CARCINOMA
Phase: NA • Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Pedaling against cancer: exercise may boost immunotherapy
Knowledge-focused OngoingThis small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…
Matched conditions: MERKEL CELL CARCINOMA
Phase: NA • Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC